Full Product Name
YARS siRNA (Human)
Product Synonym Names
Tyrosine--tRNA ligase cytoplasmic; Tyrosyl-tRNA synthetase; TyrRS
Product Gene Name
YARS sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for P54577
Specificity
YARS siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human YARS gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of YARS sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
YARS sirna
siRNA to inhibit YARS expression using RNA interference
Applications Tested/Suitable for YARS sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for YARS. It may not necessarily be applicable to this product.
NCBI Accession #
NP_003671.1
[Other Products]
NCBI GenBank Nucleotide #
NM_003680.3
[Other Products]
UniProt Primary Accession #
P54577
[Other Products]
UniProt Secondary Accession #
O43276; Q53EN1; B3KWK4; D3DPQ4[Other Products]
UniProt Related Accession #
P54577[Other Products]
Molecular Weight
59,143 Da
NCBI Official Full Name
tyrosine--tRNA ligase, cytoplasmic
NCBI Official Synonym Full Names
tyrosyl-tRNA synthetase
NCBI Official Symbol
YARS??[Similar Products]
NCBI Official Synonym Symbols
YRS; YTS; TYRRS; CMTDIC
??[Similar Products]
NCBI Protein Information
tyrosine--tRNA ligase, cytoplasmic
UniProt Protein Name
Tyrosine--tRNA ligase, cytoplasmic
UniProt Synonym Protein Names
Tyrosyl-tRNA synthetase; TyrRS
Protein Family
Tyrosine--tRNA ligase
UniProt Gene Name
YARS??[Similar Products]
UniProt Synonym Gene Names
TyrRS??[Similar Products]
UniProt Entry Name
SYYC_HUMAN
NCBI Summary for YARS
Aminoacyl-tRNA synthetases catalyze the aminoacylation of tRNA by their cognate amino acid. Because of their central role in linking amino acids with nucleotide triplets contained in tRNAs, aminoacyl-tRNA synthetases are thought to be among the first proteins that appeared in evolution. Tyrosyl-tRNA synthetase belongs to the class I tRNA synthetase family. Cytokine activities have also been observed for the human tyrosyl-tRNA synthetase, after it is split into two parts, an N-terminal fragment that harbors the catalytic site and a C-terminal fragment found only in the mammalian enzyme. The N-terminal fragment is an interleukin-8-like cytokine, whereas the released C-terminal fragment is an EMAP II-like cytokine. [provided by RefSeq, Jul 2008]
UniProt Comments for YARS
YARS: Catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr- AMP and then transferred to the acceptor end of tRNA(Tyr). Defects in YARS are the cause of Charcot-Marie-Tooth disease dominant intermediate type C (CMTDIC). CMTDIC is a form of Charcot-Marie-Tooth disease characterized by clinical and pathologic features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec. Belongs to the class-I aminoacyl-tRNA synthetase family.
Protein type: EC 6.1.1.1; Ligase
Chromosomal Location of Human Ortholog: 1p35.1
Cellular Component: extracellular space; cytoplasm; nucleus; cytosol
Molecular Function: signal transducer activity; tyrosine-tRNA ligase activity; ATP binding; isoleucine-tRNA ligase activity; interleukin-8 receptor binding; tRNA binding
Biological Process: tyrosyl-tRNA aminoacylation; isoleucyl-tRNA aminoacylation; tRNA aminoacylation for protein translation; apoptosis; gene expression; signal transduction
Disease: Charcot-marie-tooth Disease, Dominant Intermediate C
Research Articles on YARS
1. the association of rare YARS variant with late-onset autosomal dominant Charcot-Marie-Tooth neuropathy
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
